SK-10 is under clinical development by Guangzhou Zhiyi Biotechnology and currently in Phase I for Chemotherapy-Induced Diarrhea (CID). According to GlobalData, Phase I drugs for Chemotherapy-Induced Diarrhea (CID) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SK-10 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SK-10 is under development for the treatment of chemotherapy induced diarrhea. It is a bacteroides fragilis-based live biotherapeutic product (LBP). The drug candidate is administered through oral route.
Guangzhou Zhiyi Biotechnology overview
Guangzhou Zhiyi Biotechnology (Zhiyi) develops micro-ecological probiotics, biotherapeutics and biological drugs in the field of digestion and metabolic diseases. Zhiyi is headquartered in Guangzhou, Guangdong, China.
For a complete picture of SK-10’s drug-specific PTSR and LoA scores, buy the report here.